CRISPR Therapeutics' 2026 CASGEVY Plans and Pipeline Expansion Could Be a Game Changer for CRSP

CRISPR Therapeutics is expanding its CASGEVY commercialization and advancing new clinical programs, with a data-rich 2026 pipeline ahead. The company's investment narrative focuses on CASGEVY's potential to anchor a broader gene-editing franchise and manage years of losses. While this reinforces the story, execution and governance risks remain, with shares potentially trading above their fair value.